Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

653
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
653
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.9K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.9K
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

2.9K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
2.9K
Anxiolytic Drugs: Overview01:26

Anxiolytic Drugs: Overview

1.4K
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions.

Molecular psychiatry·2026
Same author

Efficacy and Safety of the Selective, Brain-Penetrant P2X7 Receptor Antagonist JNJ-55308942 (Zanvipixant) in Bipolar Depression: A Phase 2a Study.

Biological psychiatry global open science·2026
Same authorSame journal

Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD).

International clinical psychopharmacology·2026
Same author

Efficacy and Clinical Relevance of Adjunctive Cariprazine Treatment in Patients with Major Depressive Disorder: Post Hoc Analyses from a Phase III Study.

Neuropsychiatric disease and treatment·2026
Same author

Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants.

International clinical psychopharmacology·2026
Same author

Recommendations for the Deprescribing of Psychotropic Medications: A Consensus Statement From the American Society of Clinical Psychopharmacology Task Force.

JAMA network open·2026

Related Experiment Video

Updated: Mar 19, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.8K

Ziprasidone augmentation for anxious depression.

Dawn F Ionescu1, Richard C Shelton, Lee Baer

  • 1aDepartment of Psychiatry, Massachusetts General Hospital bHarvard Medical School, Boston, Massachusetts cDepartment of Psychiatry, Office of Psychiatric Clinical Research, University of Alabama at Birmingham, Birmingham, Alabama, USA.

International Clinical Psychopharmacology
|June 17, 2016
PubMed
Summary
This summary is machine-generated.

Ziprasidone augmentation effectively treated depression in patients with or without anxious depression. However, its anxiety-reducing effects were not clinically significant for those with higher anxiety levels.

More Related Videos

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

40.4K

Related Experiment Videos

Last Updated: Mar 19, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.8K
The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

40.4K

Area of Science:

  • Psychiatry
  • Clinical Pharmacology

Background:

  • Escitalopram is a common antidepressant, but some patients require augmentation for treatment-resistant depression.
  • Ziprasidone augmentation has previously shown anxiolytic effects in patients with depression.

Purpose of the Study:

  • To conduct a post-hoc analysis of a randomized trial to determine if ziprasidone augmentation is more effective in patients with anxious depression versus nonanxious depression.
  • To evaluate the efficacy of ziprasidone augmentation on depression and anxiety symptoms using moderator analysis.

Main Methods:

  • Post-hoc analysis of an 8-week, randomized, double-blind, placebo-controlled trial.
  • Comparison of changes in Hamilton Depression and Anxiety Rating Scales between patients with and without anxious depression.
  • Moderator analysis to assess the impact of baseline anxiety on treatment outcomes.

Main Results:

  • Ziprasidone augmentation showed no significant difference in improving depression scores between patients with and without anxious depression (P=0.91).
  • A trend towards significance (P=0.1) favored patients without anxious depression for anxiety score improvement.
  • While ziprasidone improved anxiety, the effect was not clinically significant in patients with higher baseline anxiety.

Conclusions:

  • Ziprasidone augmentation is equally effective for treating depression in patients with or without anxious depression.
  • The anxiolytic effect of ziprasidone augmentation in patients with higher anxiety levels did not reach clinical significance.
  • Further research may be needed to identify more effective augmentation strategies for anxious depression.